Heartbeam, Inc. Common Stock

Day range

$0.38 – $0.41

Open

$0.39

Prev close

$0.39

Volume

1.26M

Market cap

$22.16M

Shares out

56.35M

P/E

—

P/S

—

P/B

2.69

P/FCF

—

ROE

-248.2%

ROA

-190.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Public offeringAug 14, 2026

  HeartBeam, Inc. entered into an At-The-Market Equity Offering Sales Agreement with Titan Partners Securities LLC, pursuant to which the Company may sell, from time to time, an aggregate of up to $25,000,000 of its common stock. Sales of the Shares may be made in transactions that are deemed to be 'at the market offerings' pursuant to Rule 415 under the Securities Act of 1933, as amended, including by means of ordinary brokers' transactions on the Nasdaq Capital Market at market prices.

• Annual meeting resultsAug 3, 2026

  On July 31, 2026, HeartBeam, Inc. (the "Company") held an annual meeting of stockholders (the "Annual Meeting") virtually, via live webcast... The seven nominees for director were elected to serve a one-year term as follows: [detailed voting results for Richard Ferrari, Branislav Vajdic, George A. de Urioste, Marga Ortigas-Wedekind, Willem Elfrink, Kenneth Nelson, and Michael Jaff]

• Listing deficiency noticeJul 2, 2026

  On June 30, 2026, HeartBeam, Inc. received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).

• Director departureJun 24, 2026

  On June 18, 2026, Mark Strome notified the Company of his resignation from the Board and all committees thereof, effective immediately. Mr. Strome's resignation was not due to any dispute or disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

• Public offeringApr 16, 2026

  On April 14, 2026, HeartBeam, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Titan Partners Group LLC...pursuant to which the Company agreed to issue and sell in an underwritten public offering (the "Offering") an aggregate of 12,500,000 shares of the Company's common stock...The public offering price for each share of Common Stock is $0.80, and the Underwriter has agreed to purchase the shares of Common Stock...at a price for each share of Common Stock of $0.744.

Days to cover

6.2

Short interest

2.49M

Avg volume

400.91K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• How Decentralized AI is Unlocking Value in Cardiac Diagnostics
  positiveBenzinga· Mar 27, 2026
• New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $133B Cardiac Diagnostics Market
  neutralGlobeNewswire Inc.· Oct 28, 2025
• HeartBeam Cuts Costs Awaits FDA Decision
  positiveThe Motley Fool· Aug 13, 2025
• Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
  Benzinga· Mar 22, 2024
• Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
  Benzinga· Apr 11, 2023